Algert Global LLC Buys New Shares in HealthEquity, Inc. (NASDAQ:HQY)

Algert Global LLC purchased a new position in shares of HealthEquity, Inc. (NASDAQ:HQY) in the second quarter, according to its most recent filing with the SEC. The firm purchased 8,679 shares of the company’s stock, valued at approximately $748,000.

A number of other large investors have also recently bought and sold shares of HQY. Rise Advisors LLC bought a new position in HealthEquity during the first quarter worth $28,000. International Assets Investment Management LLC acquired a new stake in shares of HealthEquity in the 2nd quarter valued at about $35,000. YHB Investment Advisors Inc. bought a new stake in HealthEquity in the 1st quarter valued at about $40,000. Fidelis Capital Partners LLC acquired a new position in HealthEquity during the 1st quarter worth approximately $42,000. Finally, Parallel Advisors LLC boosted its holdings in HealthEquity by 255.5% in the fourth quarter. Parallel Advisors LLC now owns 679 shares of the company’s stock worth $45,000 after acquiring an additional 488 shares in the last quarter. 99.55% of the stock is currently owned by institutional investors and hedge funds.

HealthEquity Price Performance

Shares of NASDAQ HQY opened at $83.09 on Friday. The company has a market capitalization of $7.23 billion, a PE ratio of 90.32, a PEG ratio of 1.25 and a beta of 0.52. The company has a quick ratio of 4.10, a current ratio of 4.10 and a debt-to-equity ratio of 0.51. The stock’s 50 day moving average price is $76.47 and its 200-day moving average price is $79.17. HealthEquity, Inc. has a twelve month low of $61.81 and a twelve month high of $88.26.

HealthEquity (NASDAQ:HQY) last posted its quarterly earnings data on Tuesday, September 3rd. The company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.50 by $0.16. The business had revenue of $299.93 million for the quarter, compared to analysts’ expectations of $284.48 million. HealthEquity had a return on equity of 9.01% and a net margin of 9.61%. On average, equities analysts anticipate that HealthEquity, Inc. will post 2.25 EPS for the current year.

Insiders Place Their Bets

In related news, Director Frank Corvino sold 1,247 shares of the company’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $80.26, for a total value of $100,084.22. Following the transaction, the director now owns 4,823 shares in the company, valued at approximately $387,093.98. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other HealthEquity news, Vice Chairman Stephen Neeleman sold 35,000 shares of the stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $79.86, for a total transaction of $2,795,100.00. Following the completion of the transaction, the insider now owns 89,769 shares in the company, valued at $7,168,952.34. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Frank Corvino sold 1,247 shares of the business’s stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $80.26, for a total transaction of $100,084.22. Following the completion of the sale, the director now directly owns 4,823 shares in the company, valued at approximately $387,093.98. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 43,952 shares of company stock valued at $3,526,147. Company insiders own 2.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on HQY shares. Barrington Research restated an “outperform” rating and set a $105.00 price objective on shares of HealthEquity in a report on Friday, September 20th. Royal Bank of Canada restated an “outperform” rating and set a $92.00 price objective on shares of HealthEquity in a report on Wednesday, September 4th. Wells Fargo & Company raised their price objective on shares of HealthEquity from $107.00 to $110.00 and gave the company an “overweight” rating in a research note on Thursday, June 20th. Bank of America decreased their target price on shares of HealthEquity from $105.00 to $100.00 and set a “buy” rating for the company in a research report on Wednesday, September 4th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $105.00 price target on shares of HealthEquity in a research report on Wednesday, September 4th. Twelve research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $103.83.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.